CA2601706C - Treatment of protein degradation disorders - Google Patents

Treatment of protein degradation disorders Download PDF

Info

Publication number
CA2601706C
CA2601706C CA2601706A CA2601706A CA2601706C CA 2601706 C CA2601706 C CA 2601706C CA 2601706 A CA2601706 A CA 2601706A CA 2601706 A CA2601706 A CA 2601706A CA 2601706 C CA2601706 C CA 2601706C
Authority
CA
Canada
Prior art keywords
cells
cell
moiety
cancer
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2601706A
Other languages
English (en)
French (fr)
Other versions
CA2601706A1 (en
Inventor
Kenneth C. Anderson
James Elliott Bradner
Edward Franklin Greenberg
Teru Hideshima
Nicholas Paul Kwiatkowski
Ralph Mazitschek
Stuart L. Schreiber
Jared Shaw
Stephen J. Haggarty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Harvard University
Original Assignee
Dana Farber Cancer Institute Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Harvard University filed Critical Dana Farber Cancer Institute Inc
Priority to CA2937005A priority Critical patent/CA2937005A1/en
Publication of CA2601706A1 publication Critical patent/CA2601706A1/en
Application granted granted Critical
Publication of CA2601706C publication Critical patent/CA2601706C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
CA2601706A 2005-03-22 2006-03-22 Treatment of protein degradation disorders Expired - Fee Related CA2601706C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2937005A CA2937005A1 (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66447005P 2005-03-22 2005-03-22
US60/664,470 2005-03-22
PCT/US2006/010676 WO2006102557A2 (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2937005A Division CA2937005A1 (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders

Publications (2)

Publication Number Publication Date
CA2601706A1 CA2601706A1 (en) 2006-09-28
CA2601706C true CA2601706C (en) 2016-09-20

Family

ID=37024659

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2601706A Expired - Fee Related CA2601706C (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders
CA2937005A Abandoned CA2937005A1 (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2937005A Abandoned CA2937005A1 (en) 2005-03-22 2006-03-22 Treatment of protein degradation disorders

Country Status (8)

Country Link
US (3) US8999289B2 (enExample)
EP (3) EP1861126A4 (enExample)
JP (4) JP5744376B2 (enExample)
CN (1) CN101495116A (enExample)
AU (1) AU2006226861B2 (enExample)
CA (2) CA2601706C (enExample)
SG (1) SG171690A1 (enExample)
WO (1) WO2006102557A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
MX2007013494A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag.
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
RU2420279C3 (ru) 2005-08-03 2017-03-14 Новартис Аг Применение ингибиторов hdac для лечения миеломы
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
WO2007095584A2 (en) 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2008054767A2 (en) * 2006-10-30 2008-05-08 University Of Southern California N4 modifications of pyrimidine analogs and uses thereof
CN101528037A (zh) * 2006-11-03 2009-09-09 默克公司 使用saha和硼替佐米治疗多发性骨髓瘤的方法
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2009152462A2 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The University Of Illinois Method of regulating cell growth using a proteasome inhibitor
AU2009274549B2 (en) * 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
US20120142634A1 (en) * 2008-11-10 2012-06-07 Mount Sinai School Of Medicine Of New York University Method of Treating Cancer with a Combination of a Proteasome Inhibitor and Salubrinal
CA2767697C (en) * 2009-07-06 2014-10-14 Memorial Sloan-Kettering Cancer Center Hdac 6 inhibitor-based methods for treating cancer
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US9597346B2 (en) * 2010-01-15 2017-03-21 Cornell University Methods for reducing protein levels in a cell
PH12012501492B1 (en) 2010-01-22 2020-01-24 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
JP5469779B2 (ja) * 2010-04-19 2014-04-16 エスアールアイ インターナショナル 多発性骨髄腫の治療のための組成物および方法
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US9476889B2 (en) * 2011-02-24 2016-10-25 Basilea Pharmaceutica Ag Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
EP2508510A1 (en) 2011-04-06 2012-10-10 Ikerchem, S.L. Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
JP6374392B2 (ja) * 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
US20150320723A1 (en) * 2013-01-07 2015-11-12 St. Jude Children's Research Hospital Use of Small Molecule Unfolder Protein Response Modulators to Treat Tumors With Active Sonic Hedgehog (SSH) Signaling Due To Smoothened (SMO) Mutation
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
EP3021874B1 (en) * 2013-07-18 2022-04-27 The University of Hong Kong Methods for classifying pleural fluid
WO2015054099A1 (en) 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors
US9278963B2 (en) 2013-10-10 2016-03-08 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015084905A1 (en) 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤による白血病の治療
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2972740A1 (en) * 2015-01-14 2016-07-21 Universite D'aix-Marseille Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
EP3303306B1 (en) 2015-06-08 2020-02-12 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
JP6873053B2 (ja) 2015-06-08 2021-05-19 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． タンパク質脱アセチル化阻害剤の製造方法
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
GB201609786D0 (en) * 2016-06-03 2016-07-20 Karus Therapeutics Ltd Compounds and method of use
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
ES2929032T3 (es) 2016-08-08 2022-11-24 Acetylon Pharmaceuticals Inc Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CN108239656A (zh) * 2016-12-27 2018-07-03 天津天锐生物科技有限公司 一种小分子药物控制的蛋白功能开关系统
ES2923022T3 (es) * 2017-01-31 2022-09-22 Univ Leland Stanford Junior Agentes que inhiben Ngly1 y métodos de uso de los mismos
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
US12419832B2 (en) 2018-01-29 2025-09-23 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
EP3773576A4 (en) 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
WO2021060567A1 (en) 2019-09-27 2021-04-01 Takeda Pharmaceutical Company Limited 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
AU2020412324A1 (en) 2019-12-26 2022-07-07 Centre D'etude Des Cellules Souches (Cecs) Combination of a proteasome inhibitor and a HDAC inhibitor and its use for the treatment of genetic diseases linked to a protein conformational disorder
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
PL247748B1 (pl) * 2022-03-18 2025-08-25 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Związek niskocząsteczkowy do zastosowania w leczeniu ataksji rdzeniowo-móżdżkowej typu 3
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4410284A1 (en) 2023-02-02 2024-08-07 Apteeus Compound and method for the treatment of zellweger spectrum disorder
CN120842303A (zh) * 2025-07-07 2025-10-28 江南大学 具有urat1抑制活性的二肽及其在高尿酸血症药物中的应用

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US523781A (en) * 1894-07-31 Ice-cream freezer
HU165117B (enExample) 1971-08-12 1974-06-28
US4160866A (en) * 1976-04-30 1979-07-10 Imperial Chemical Industries Limited Carbamates
DE3242252A1 (de) * 1982-11-15 1984-05-17 Bayer Ag, 5090 Leverkusen Heterocyclisch substituierte hydroxyalkyl-azolyl-derivate
NL194579C (nl) 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4608390A (en) * 1985-04-26 1986-08-26 Abbott Laboratories Lipoxygenase inhibiting compounds
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
US4861798A (en) * 1986-12-29 1989-08-29 Bristol-Myers Company Lipoxygenase inhibitory compounds
US4820828A (en) * 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
ES2008962A6 (es) 1987-12-17 1989-08-16 Marga Investigacion Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
JPH01224381A (ja) 1988-03-04 1989-09-07 Japan Tobacco Inc トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。
EP0347381B1 (de) * 1988-06-13 1992-02-12 Ciba-Geigy Ag Ungesättigte beta-Ketoesteracetale und ihre Anwendungen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO1991000257A1 (en) 1989-06-30 1991-01-10 The Trustees Of Columbia University In The City Of New York Novel potent inducers of terminal differentiation and methods of use thereof
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1991007087A1 (en) 1989-11-13 1991-05-30 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5304121A (en) * 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2659648B1 (fr) 1990-03-13 1993-02-12 Michelin Rech Tech Procede pour preparer un produit aromatique alkyle avec une zeolithe d'alkylation et une zeolithe de dealkylation.
JPH0422948A (ja) 1990-05-18 1992-01-27 Fuji Photo Film Co Ltd 写真用処理組成物及び処理方法
EP0720049B1 (en) 1990-05-09 1999-08-04 Fuji Photo Film Co., Ltd. Photographic processing composition and processing method using the same
US5045538A (en) * 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE69132531T2 (de) 1990-12-06 2001-09-13 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verbindungen und ihre Verwendung in einer binären Synthesestrategie
EP0501919A1 (de) * 1991-03-01 1992-09-02 Ciba-Geigy Ag Strahlungsempfindliche Zusammensetzungen auf der Basis von Polyphenolen und Acetalen
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5225173A (en) * 1991-06-12 1993-07-06 Idaho Research Foundation, Inc. Methods and devices for the separation of radioactive rare earth metal isotopes from their alkaline earth metal precursors
AU2677592A (en) 1991-09-13 1993-04-27 New England Deaconess Hospital Erythropoietin potentiating agents and methods for their use
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
EP0570594B1 (en) * 1991-12-10 1997-07-30 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide
US5359115A (en) * 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
JP3356304B2 (ja) 1992-06-16 2002-12-16 財団法人生産開発科学研究所 抗炎、抗潰瘍剤
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
KR100310939B1 (ko) 1992-10-01 2002-06-20 추후제출 태그로암호화한복합조합화학라이브러리
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5440016A (en) * 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
US5659016A (en) 1994-09-22 1997-08-19 Cancer Institute RPDL protein and DNA encoding the same
US6231600B1 (en) * 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP3330781B2 (ja) 1995-05-22 2002-09-30 三菱エンジニアリングプラスチックス株式会社 ポリカーボネート樹脂組成物
WO1997011366A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
EP0774464B1 (en) 1995-10-17 2004-07-28 Combichem, Inc. A template for solution phase synthesis of combinatorial libraries
JPH09124918A (ja) 1995-10-30 1997-05-13 Mitsubishi Eng Plast Kk ポリカーボネート樹脂組成物
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6068987A (en) * 1996-09-20 2000-05-30 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6190619B1 (en) 1997-06-11 2001-02-20 Argonaut Technologies, Inc. Systems and methods for parallel synthesis of compounds
US5891507A (en) * 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6195612B1 (en) * 1998-01-05 2001-02-27 Tama L. Pack-Harris Pharmacy benefit management system and method of using same
US6503708B1 (en) * 1998-01-26 2003-01-07 Incyte Genomics, Inc. Microtubule-associated protein
US6428960B1 (en) * 1998-03-04 2002-08-06 Onyx Pharmaceuticals, Inc. Selection method for producing recombinant baculovirus
US6037361A (en) * 1998-03-09 2000-03-14 Warner-Lambert Company Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) * 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
DE19846008A1 (de) 1998-10-06 2000-04-13 Bayer Ag Phenylessigsäure-heterocyclylamide
TR200101663T2 (tr) 1998-12-10 2001-11-21 F.Hoffmann-La Roche Ag Pro-kollajen c-proteinaz inhibitörleri
AU3118200A (en) 1998-12-14 2000-07-03 Merck & Co., Inc. Hiv integrase inhibitors
CA2355075C (en) 1998-12-16 2009-12-08 Aventis Pharma Limited Heteroaryl-cyclic acetals
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6258121B1 (en) * 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
EP1748046A3 (en) * 1999-11-23 2007-08-22 Methylgene, Inc. Inhibitors of histone deacetylase
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US20030129724A1 (en) * 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US7244853B2 (en) * 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
WO2002089782A2 (en) 2001-05-09 2002-11-14 President And Fellows Of Harvard College Dioxanes and uses thereof
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2003221398A (ja) 2001-11-22 2003-08-05 Japan Science & Technology Corp 蛍光又は発色基質を用いたヒストンデアセチラーゼ活性測定法
US6517889B1 (en) * 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
AU2002362030A1 (en) * 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
CN101259120B (zh) * 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
NO20032183L (no) 2002-05-15 2003-11-17 Schering Ag Histon-deacetylase-inhibitor og anvendelse derav
JP2004043446A (ja) 2002-05-15 2004-02-12 Schering Ag ヒストンデアセチラーゼ抑制剤及びその使用
WO2003101481A1 (en) * 2002-06-03 2003-12-11 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
US6726705B2 (en) 2002-06-25 2004-04-27 Incisive Surgical, Inc. Mechanical method and apparatus for bilateral tissue fastening
TW200420573A (en) * 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
AU2003273701A1 (en) * 2002-10-17 2004-05-04 Methylgene Inc. Inhibitors of histone deacetylase
EP1565193B1 (en) * 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
JP4790594B2 (ja) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
WO2005007091A2 (en) 2003-07-07 2005-01-27 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US7842835B2 (en) * 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005012247A1 (en) 2003-07-30 2005-02-10 Hôpital Sainte-Justine Compounds and methods for the rapid quantitative analysis of proteins and polypeptides
SI1663194T1 (sl) 2003-08-26 2010-08-31 Merck Hdac Res Llc Uporaba SAHA za zdravljenje mezotelioma
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
JP4989976B2 (ja) 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての３−３−二置換オキシインドール
WO2006006080A2 (en) 2004-07-08 2006-01-19 Bizmedic Co., Ltd. Sodium channel agonist
SG157365A1 (en) * 2004-12-03 2009-12-29 Dana Farber Cancer Inst Inc Compositions and methods for treating neoplastic diseases
CA2590334A1 (en) 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
US20070062152A1 (en) * 2005-09-12 2007-03-22 Nokia Corporation Domesheet assembly in a keyboard
TWM290175U (en) * 2005-09-20 2006-05-01 Chian-Hung Ju Structure of the light building materials with sound absorption and insulation function
US7438916B2 (en) * 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
WO2007095584A2 (en) * 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
US8222423B2 (en) * 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
EP2007383A4 (en) 2006-03-22 2010-09-15 Univ California HEMMER OF PROTEIN PRENYL TRANSFERASES
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US20070282010A1 (en) * 2006-05-30 2007-12-06 Bridge Pharma, Inc. Methods of Accelerating Muscle Growth, Decreasing Fat Deposits and Improving Feed Efficiency in Livestock Animals
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CN105481788A (zh) * 2006-10-28 2016-04-13 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
JP2011500783A (ja) 2007-10-22 2011-01-06 オーキッド リサーチ ラボラトリーズ リミテッド ヒストンデアセチラーゼ阻害剤
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US8467034B2 (en) * 2008-07-02 2013-06-18 Nikon Corporation Light shielding unit, variable slit apparatus, and exposure apparatus
AU2009274549B2 (en) * 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
WO2010019924A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US20130040998A1 (en) * 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2006102557A2 (en) 2006-09-28
EP2491926A1 (en) 2012-08-29
EP3354265A1 (en) 2018-08-01
US10172905B1 (en) 2019-01-08
JP5744376B2 (ja) 2015-07-08
JP2013053157A (ja) 2013-03-21
AU2006226861A1 (en) 2006-09-28
EP1861126A4 (en) 2009-11-18
JP2017190338A (ja) 2017-10-19
EP2491926B1 (en) 2018-05-09
AU2006226861B2 (en) 2012-08-16
SG171690A1 (en) 2011-06-29
WO2006102557A3 (en) 2009-04-16
US20060239909A1 (en) 2006-10-26
CA2937005A1 (en) 2006-09-28
CN101495116A (zh) 2009-07-29
EP1861126A2 (en) 2007-12-05
CA2601706A1 (en) 2006-09-28
US8999289B2 (en) 2015-04-07
US9572854B2 (en) 2017-02-21
US20160051619A1 (en) 2016-02-25
JP2009509910A (ja) 2009-03-12
JP2014224158A (ja) 2014-12-04

Similar Documents

Publication Publication Date Title
CA2601706C (en) Treatment of protein degradation disorders
CN113164495B (zh) E3连接酶的共价靶向
US20240307359A1 (en) Method of screening for agents for differentiating stem cells
JP6165748B2 (ja) 脱ユビキチン活性の阻害方法
US20150150869A1 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
WO2008134474A2 (en) Compositions and methods including cell death inducers and procaspase activation
Rebbaa et al. Factors secreted by human neuroblastoma mediate doxorubicin resistance by activating STAT3 and inhibiting apoptosis
Ling et al. Development of novel amino-quinoline-5, 8-dione derivatives as NAD (P) H: quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities
Das et al. 3, 5-Bis (benzylidene)-1-[4-2-(morpholin-4-yl) ethoxyphenylcarbonyl]-4-piperidone hydrochloride: A lead tumor-specific cytotoxin which induces apoptosis and autophagy
Wang et al. Targeting procaspase‐3 with WF‐208, a novel PAC‐1 derivative, causes selective cancer cell apoptosis
Fu et al. Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression in vitro and in vivo
Romagnoli et al. Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents
US9134329B2 (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell
US8008354B2 (en) Death receptor sensitizing compounds and methods of use therefor
WO2009023846A2 (en) Methods for heat shock protein dependent cancer treatment
HK1175115A (en) Treatment of protein degradation disorders
HK1175115B (en) Treatment of protein degradation disorders
AU2005267117C1 (en) Inhibition of NF-KB
US20070270455A1 (en) INHIBITION OF NF-kB
US20030229132A1 (en) Small molecule modulators of apoptosis
HK1133401A (en) Treatment of protein degradation disorders
WO2021064175A1 (en) Compounds for preventing migration of cancer cells
Dasa et al. CIHR A

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831